{
    "nctId": "NCT00720031",
    "officialTitle": "Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones",
    "inclusionCriteria": "* HLA-A2 melanoma patients with :\n\n  * either loco-regional or lymph node metastasis\n  * transit nodules not surgically resectable\n  * measurable cutaneous or visceral metastasis\n* Patients' tumor express Melan-A/MART-1 antigen.\n* No chemotherapy treatment (except for Deticene used before the first T cell clones infusion) or radiotherapy or immunotherapy in the last 4 weeks before infusion.\n* No other melanoma treatment during the protocol.\n* Life expectancy should be greater than 6 months.\n* General state with Karnowsky greater than 80, ECOG = 0, 1 or 2.\n* Patient should be negative for HIV and B and C hepatitis.\n* Biological parameters at the beginning of the study: leucocytes \u00b3 2000 elements per mm3, hemoglobin \u00b3 10.5g/dl, platelets \u00b3 100 000 per mm3, phosphatases alcalines transaminases \u00a3 1 time 1/2 compared to the normal.\n* Signed informed consent\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "* Cardio-vascular pathologies, evoluting and uncontrolled, (severe HTA), cardiac deficiency, severe angor, severe arrhythmia.\n* Infectious pathologies evoluting and requiring antibiotherapy.\n* Patients HIV+.\n* Transplanted patients or patients suffering from severe auto-immune disease.\n* Psychiatric troubles that do not allow the protocol follow-up.\n* Pregnant or breast-feeding women.\n* No contraception."
}